To present, several studies reported that around 50% of basal cell carcinomas resistant to Smo inhibitors have Smo mutations, Importantly, further analysis revealed that about 17% of basal cell carcinoma drug resistance found SmoD473 site mutation [51, 52]. The gene discussed is SMO; the disease is basal cell carcinoma.